3-甲氧基-3H-[1,2,3]三唑并[4,5-b]吡啶 | 61822-85-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 中文名称: 3-甲氧基-3H-[1,2,3]三唑并[4,5-b]吡啶
• 英文名称: 7-aza-1-methoxybenzotriazole
• 英文别名: 3-methoxy-3H-[1,2,3]triazolo[4,5-b]pyridine；3-Methoxy-triazolo<4,5-b>pyridin；3-Methoxytriazolo[4,5-b]pyridine
• CAS: 61822-85-3
• 化学式: C₆H₆N₄O
• 分子量: 150.14
• InChiKey: ZVMICLBLTULFOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  52.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-甲氧基-3H-[1,2,3]三唑并[4,5-b]吡啶 在 sodium thiophenolate 作用下， 以 氘代二甲亚砜 、 氘代氯仿 为溶剂， 生成 N-羟基-7-氮杂苯并三氮唑
  参考文献：
  名称：

  Comparison of the Effects of 5- and 6-HOAt on Model Peptide Coupling Reactions Relative to the Cases for the 4- and 7-Isomers^,

  摘要：

  [GRAPHICS]Synthesis of 5- and 6-HOAt has completed the full set of the four HOAt isomers derived from HOBt by insertion of a single nitrogen atom in the benzenoid nucleus. Comparison of the reactivity of all four isomers in model peptide coupling reactions has confirmed the unique character of the 7-isomer in promoting selectivity and maintaining configuration at the reactive carboxylic acid residue.

  DOI：

  10.1021/ol006013z
• 作为产物：
  描述：

  N-羟基-7-氮杂苯并三氮唑 、 硫酸二甲酯 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 以100%的产率得到3-甲氧基-3H-[1,2,3]三唑并[4,5-b]吡啶
  参考文献：
  名称：

  Comparison of the Effects of 5- and 6-HOAt on Model Peptide Coupling Reactions Relative to the Cases for the 4- and 7-Isomers^,

  摘要：

  [GRAPHICS]Synthesis of 5- and 6-HOAt has completed the full set of the four HOAt isomers derived from HOBt by insertion of a single nitrogen atom in the benzenoid nucleus. Comparison of the reactivity of all four isomers in model peptide coupling reactions has confirmed the unique character of the 7-isomer in promoting selectivity and maintaining configuration at the reactive carboxylic acid residue.

  DOI：

  10.1021/ol006013z

文献信息

• BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE
  申请人：Pfizer Inc.

  公开号：US20160271270A1

  公开（公告）日：2016-09-22

  The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula: F 1 -L 1 -T-L 2 -F 2 where F 1 , L 1 , T, L 2 and F 2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.

  本发明涉及新颖的具有双重功能的CTI-CTI和CBI-CTI二聚物，其公式为： F1-L1-T-L2-F2 其中F1、L1、T、L2和F2如本文所述定义，用于治疗增殖性疾病，其中发明的二聚物可以作为独立药物、抗体药物偶联物（ADCs）中的有效载荷以及与生产或施用此类ADCs相关的连接器有效载荷化合物；以及包括前述二聚物、连接器有效载荷和ADCs的组合物，以及使用这些二聚物、连接器有效载荷和ADCs治疗包括癌症在内的病理状况的方法。
• [EN] SPLICEOSTATIN ANALOGS<br/>[FR] ANALOGUES DE SPLICÉOSTATINE
  申请人：PFIZER

  公开号：WO2014068443A1

  公开（公告）日：2014-05-08

  The present invention is directed to novel cytotoxic spliceostatin analogs (I) and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.

  本发明涉及新型细胞毒性剪接抑制素类似物（I）及其衍生物，涉及其抗体药物结合物，以及使用它们治疗包括癌症在内的医疗状况的方法。
• [EN] TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION<br/>[FR] ANALOGUES DE LA TUBULYSINE ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：PFIZER

  公开号：WO2017134547A1

  公开（公告）日：2017-08-10

  The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.

  本发明涉及新的细胞毒性的管素类似物和衍生物，以及它们的抗体药物偶联物，以及使用它们治疗包括癌症在内的医疗状况的方法。
• Facile synthesis of 1-alkoxy-1<i>H</i>-benzo- and 7-azabenzotriazoles from peptide coupling agents, mechanistic studies, and synthetic applications
  作者：Mahesh K Lakshman、Manish K Singh、Mukesh Kumar、Raghu Ram Chamala、Vijayender R Yedulla、Domenick Wagner、Evan Leung、Lijia Yang、Asha Matin、Sadia Ahmad

  DOI：10.3762/bjoc.10.200

  日期：——

  utility, this novel reaction has been used to prepare a series of acyclic nucleoside-like compounds. Because BtO(-) is a nucleofuge, several Bt-OCH2Ar substrates have been evaluated in nucleophilic substitution reactions. Finally, the possible formation of Pd pi-allyl complexes by departure of BtO(-) has been queried. Thus, alpha-allylation of three cyclic ketones was evaluated with 1-(cinnamyloxy)-1H-benzo[d][1

  (1H-苯并[d][1,2,3]三唑-1-基氧基)三(二甲氨基)鏻六氟磷酸盐(BOP)，1H-苯并[d][1,2,3]三唑-1-基4-甲基苯磺酸盐 (Bt-OTs) 和 3H-[1,2,3]三唑并[4,5-b]吡啶-3-基 4-甲基苯磺酸盐 (At-OTs) 通常用于肽合成中形成酰胺键。然而，这些化合物与醇在碱存在下发生先前未描述的反应，产生1-烷氧基-1H-苯并-(Bt-OR)和7-氮杂苯并三唑(At-OR)。尽管 BOP 与醇反应生成 1-烷氧基-1H-苯并三唑，但 Bt-OT 被证明更优越。伯醇和仲醇都在通常温和的反应条件下进行反应。相应地，由At-OTs合成了1-烷氧基-1H-7-氮杂苯并三唑。从机理上讲，这些肽偶联剂可通过三种途径与醇发生反应。从(31)P(1)H}、[(18)O]-标记和其他化学实验来看，醇的鏻和甲苯磺酸衍生物似乎是中间体。然后它们与原位产生的 BtO(-) 和
• BIFUNCTIONAL CYTOTOXIC AGENTS
  申请人：Pfizer Inc.

  公开号：US20150209445A1

  公开（公告）日：2015-07-30

  Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.

  细胞毒性二聚体包括基于CBI和/或CPI的亚单位，包括这种二聚体的抗体药物结合物，以及使用它们治疗癌症和其他疾病的方法。